The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Open accessAbstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158 · cited 1×
“All individuals fulfilled the following inclusion criteria: (1) no significant alcohol consumption (the definition of significant alcohol consumption has been inconsistent and ranged from 41 alcoholic beverage (10 g of alcohol per one drink unit) per day to 440 g per day); (2) no significant acute or chronic inflammat…”
BackgroundKanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Brown and beige fat: Development, function and therapeutic potential
Harms, M., & Seale, P. (2013) · Nature Medicine · doi:10.1038/nm.3361 · Cited by 2,328
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Cited by
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Signals from the gut microbiota to distant organs in physiology and disease
Schroeder, B. O., & Bäckhed, F. (2016) · Nature Medicine · doi:10.1038/nm.4185 · Cited by 1,409
Gut microbial metabolites as multi-kingdom intermediates
Krautkramer, K. A., Fan, J., & Bäckhed, F. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0438-4 · Cited by 1,398
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Gut microbiota-derived metabolites as central regulators in metabolic disorders
Agus, A., Clément, K., & Sokol, H. (2021) · Gut · doi:10.1136/gutjnl-2020-323071 · Cited by 1,347
Dietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
“Several studies indicate that inhibition of intestinal FXR improves metabolic phenotypes [75, 77] but the underlying mechanisms are still unknown.”
BackgroundGut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Self-citationChávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
“At this regard, a T-β-MCA derivative, the glycine-β-muricholic acid (Gly-MCA), was administered to experimental models of NAFLD showing reduction of obesity, insulin resistance and degree of liver disease [162].”
MethodNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Li, G., Xie, C., Lu, S., Nichols, R. G., Tian, Y., Li, L., Patel, D., Ma, Y., Brocker, C. N., Yan, T., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.019 · Cited by 667
Self-citationRole of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Pathak, P., Xie, C., Nichols, R. G., Ferrell, J. M., Boehme, S., Krausz, K. W., Patterson, A. D., Gonzalez, F. J., & Chiang, J. Y. L. (2018) · Hepatology · doi:10.1002/hep.29857 · Cited by 567
Self-citationThe role of the gut microbiome and its metabolites in metabolic diseases
Wu, J., Wang, K., Wang, X., Pang, Y., & Jiang, C. (2021) · Protein & Cell · doi:10.1007/s13238-020-00814-7 · Cited by 557
Self-citationThe impact of the gut microbiota on the reproductive and metabolic endocrine system
Qi, X., Yun, C., Pang, Y., & Qiao, J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1894070 · Cited by 554
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 544
Bile Acid Metabolism in Liver Pathobiology
Chiang, J. Y. L., & Ferrell, J. M. (2018) · Gene Expression · doi:10.3727/105221618x15156018385515 · Cited by 546
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Self-citationMolecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis
Hao, H., Cao, L., Jiang, C., Che, Y., Zhang, S., Takahashi, S., Wang, G., & Gonzalez, F. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.007 · Cited by 469
“Dysregulation of bile acid homeostasis was also found in a set of other diseases including colitis and its associated cancer, diabetes, obesity, and various liver diseases (Cully, 2015; Fang et al., 2015; Jiang et al., 2015; Ryan et al., 2014; Zhou et al., 2014).”
BackgroundSelf-citationBile acids in glucose metabolism in health and disease
Shapiro, H., Kolodziejczyk, A. A., Halstuch, D., & Elinav, E. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171965 · Cited by 464
Role of bile acids in metabolic control
Molinaro, A., Wahlström, A., & Marschall, H.-U. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.11.002 · Cited by 447
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 435
Self-citationBile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 437
“Further studies of intestine-specific Fxr−/− mice and antagonism of intestinal FXR by glycine-MCA demonstrated that intestinal FXR played a critical role in protecting against DIO and diabetes (61, 62).”
BackgroundYou Are What You Eat—The Relationship between Diet, Microbiota, and Metabolic Disorders—A Review
Moszak, M., Szulińska, M., & Bogdański, P. (2020) · Nutrients · doi:10.3390/nu12041096 · Cited by 397
“[179] reported that treatment of obese mice with glycine-βmuricholic acid (Gly-MCA) inhibited FXR signaling in the intestine and, therefore, improved metabolic parameters.”
BackgroundAn Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 372
Self-citationLiu, Y., Chen, K., Li, F., Gu, Z., Liu, Q., He, L., Shao, T., Song, Q., Zhu, F., Zhang, L., et al. (2020) · Hepatology · doi:10.1002/hep.30975 · Cited by 364
“To test this hypothesis, mice were treated with an intestine-specific FXR inhibitor, Gly-MCA, which has been identified as an orally available, small molecule, intestine-selective FXR inhibitor and is not hydrolyzed by gut bacterial BSH.(16) As expected, Gly-MCA did not suppress liver Shp expression, but the intestina…”
MethodSelf-citationCeramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs
Ahmad, T. R., & Haeusler, R. A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0266-7 · Cited by 337
Sphingolipids in metabolic disease: The good, the bad, and the unknown
Green, C. D., Maceyka, M., Cowart, L. A., & Spiegel, S. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.006 · Cited by 327
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
Takahashi, S., Fukami, T., Masuo, Y., Brocker, C. N., Xie, C., Krausz, K. W., Wolf, C. R., Henderson, C. J., & Gonzalez, F. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m071183 · Cited by 313
“controls FXR signaling and metabolic disease in mouse models of obesity (7-9).”
BackgroundSelf-citationMetabolic Messengers: ceramides
Summers, S. A., Chaurasia, B., & Holland, W. L. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0134-8 · Cited by 299
Gut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297
“Conversely, however, the small molecule Gly-MCA, that inhibits intestinal FXR signaling, reverses diet-induced and genetic obesity in mice, leaving the optimal strategy to target gut FXR unsettled (Jiang et al., 2015).”
BackgroundBile acid metabolism and signaling in liver disease and therapy
Chiang, J. Y. L. (2017) · Liver Research · doi:10.1016/j.livres.2017.05.001 · Cited by 294
“Consistent with this, the intestine-selective FXR inhibitor GlyMCA, which is not absorbed into the circulation, increases T-MCAs and prevents obesity and NAFLD in mice [34].”
BackgroundDiscovery of farnesoid X receptor and its role in bile acid metabolism
Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 288
Hartmann, P., Hochrath, K., Horvath, A., Chen, P., Seebauer, C. T., Llorente, C., Wang, L., Alnouti, Y., Fouts, D. E., Stärkel, P., et al. (2018) · Hepatology · doi:10.1002/hep.29676 · Cited by 290
“It has been shown that deficiency or inhibition of intestinal FXR (by administration of glyco-betaMCA, tauro-beta-MCA, or tempol) alleviates obesity and NAFLD in mice.((44,45)) However, in ALD, deficiency of FXR worsens liver damage,((46,47)) and agonizing FXR activity systemically improves ALD.”
A selective gut bacterial bile salt hydrolase alters host metabolism
Yao, L., Seaton, S. C., Ndousse-Fetter, S., Adhikari, A. A., DiBenedetto, N., Mina, A. I., Banks, A. S., Bry, L., & Devlin, A. S. (2018) · eLife · doi:10.7554/elife.37182 · Cited by 274
“In addition, we performed a relatively short diet intervention compared to other studies that have used HFD to study metabolic changes (Jiang et al., 2015; Joyce et al., 2014; Rao et al., 2016; Serino et al., 2012), and we did not expect to observe significant changes in body weight over the course of a shorter experi…”
Polyphenol Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review
Chambers, K. F., Day, P. E., Aboufarrag, H. T., & Kroon, P. A. (2019) · Nutrients · doi:10.3390/nu11112588 · Cited by 262
“Abbreviations BA bile acid Cyp7a1 cholesterol 7 alpha-hydroxylase RCT reverse cholesterol transport HDL high-density lipoprotein LDL low-density lipoprotein FXR farnesoid X receptor BSH bile salt hydrolase HF high-fat CDCA chenodeoxycholic acid”
ResultInfluentialDietary fat, bile acid metabolism and colorectal cancer
Ocvirk, S., & O’Keefe, S. J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.003 · Cited by 262
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Pathak, P., Liu, H., Boehme, S., Xie, C., Krausz, K. W., Gonzalez, F., & Chiang, J. Y. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784322 · Cited by 253
“Paradoxically, deficiency or antagonism of intestine FXR was shown to improve obesity, insulin resistance, and NAFLD (11, 12), but activation of intestinal FXR also improves metabolic disease in diabetic mice (13).”
BackgroundSelf-citationAnimal models to study bile acid metabolism
Li, J., & Dawson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.011 · Cited by 255
Self-citationA dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility
Wei, M., Huang, F., Zhao, L., Zhang, Y., Yang, W., Wang, S., Li, M., Han, X., Ge, K., Qu, C., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102766 · Cited by 253
“It has been shown that inhibition of intestinal FXR/FGF15 signaling exerts beneficial effects on obesity associated metabolic dysfunction [24].”
BackgroundZhou, J., & Yin, Y. (2016) · The Analyst · doi:10.1039/c6an01753c · Cited by 245
Adipocyte Ceramides Regulate Subcutaneous Adipose Browning, Inflammation, and Metabolism
Chaurasia, B., Kaddai, V. A., Lancaster, G. I., Henstridge, D. C., Sriram, S., Galam, D. L. A., Gopalan, V., Prakash, K. N. B., Velan, S. S., Bulchand, S., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.002 · Cited by 247
Non-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241
“To dissect the tissue-specific function of FXR-bile acid in the gut, intestinal-specific FXR deficient mice [117,118],were fed with HFD.”
BackgroundFarnesoid X receptor (FXR): Structures and ligands
Jiang, L., Zhang, H., Xiao, D., Wei, H., & Chen, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.029 · Cited by 231
“Gly-MCA is a potential candidate to treat metabolic disease owing to its selective inhibition of the intestine FXR rather than the hepatic FXR [100].”
BackgroundFXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Wang, X. X., Wang, D., Luo, Y., Myakala, K., Dobrinskikh, E., Rosenberg, A. Z., Levi, J., Kopp, J. B., Field, A., Hill, A., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017020222 · Cited by 222
Self-citationHerbal drug discovery for the treatment of nonalcoholic fatty liver disease
Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.017 · Cited by 224
Self-citationBile Acid Signaling in Inflammatory Bowel Diseases
Fiorucci, S., Carino, A., Baldoni, M., Santucci, L., Costanzi, E., Graziosi, L., Distrutti, E., & Biagioli, M. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06715-3 · Cited by 224
Metabolic Messengers: bile acids
Perino, A., & Schoonjans, K. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00559-z · Cited by 223
Intestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215
Targeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
Self-citationRao, A., Kosters, A., Mells, J. E., Zhang, W., Setchell, K. D. R., Amanso, A. M., Wynn, G. M., Xu, T., Keller, B. T., Yin, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4823 · Cited by 211
“Administration of an ASBTi does not alter ceramides in HFD-fed mouse ileum or liver Recent studies in a different HFD-fed mouse model (8, 18) support a role for ileal FXR signaling–associated changes in ceramide synthesis and secretion into the portal circulation in the development of fatty liver”
BackgroundZhao, Q., Dai, M.-Y., Huang, R.-Y., Duan, J.-Y., Zhang, T., Bao, W.-M., Zhang, J.-Y., Gui, S.-Q., Xia, S.-M., Dai, C.-T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37459-z · Cited by 208
Self-citationImpact of Gut Microbiota on Host Glycemic Control
Gérard, C., & Vidal, H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00029 · Cited by 209
“Most publications indicate that activation of intestinal FXR has a negative impact on host glycemic control in the obese state, suggesting that inhibition of intestinal FXR signaling might be efficient for managing hyperglycemia (97, 98).”
BackgroundThe metabolic impact of small intestinal nutrient sensing
Duca, F. A., Waise, T. M. Z., Peppler, W. T., & Lam, T. K. T. (2021) · Nature Communications · doi:10.1038/s41467-021-21235-y · Cited by 205
Towards a multidisciplinary approach to understand and manage obesity and related diseases
Bischoff, S. C., Boirie, Y., Cederholm, T., Chourdakis, M., Cuerda, C., Delzenne, N. M., Deutz, N. E., Fouque, D., Genton, L., Gil, C., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.11.007 · Cited by 206
“For example, recent studies revealed that orally administered glycine-b-muricholic acid, an inhibitor of the farnesoid X receptor in the gut, improves metabolic parameters in mouse models of obesity [24].”
BackgroundGuan, B., Tong, J., Hao, H., Yang, Z., Chen, K., Xu, H., & Wang, A. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.011 · Cited by 202
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 204
“Further, the synthesis of ceramide pools throughout the body was reported to be regulated by the BA/FXR axis in the ileum and cecum [176].”
BackgroundThe biosynthesis, signaling, and neurological functions of bile acids
Kiriyama, Y., & Nochi, H. (2019) · Biomolecules · doi:10.3390/biom9060232 · Cited by 204
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Sun, L., Pang, Y., Wang, X., Wu, Q., Liu, H., Liu, B., Liu, G., Ye, M., Kong, W., & Jiang, C. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.02.004 · Cited by 204
Self-citationThe gut microbiome: a core regulator of metabolism
Fujisaka, S., Watanabe, Y., & Tobe, K. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0111 · Cited by 203
An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
Xie, C., Jiang, C., Shi, J., Gao, X., Sun, D., Sun, L., Wang, T., Takahashi, S., Anitha, M., Krausz, K. W., et al. (2017) · Diabetes · doi:10.2337/db16-0663 · Cited by 201
“However, in the intestine, FXR activation impaired energy expenditure, and further aggravated obesity and glucose intolerance (22), whereas intestinal FXR inhibition exerted metabolic benefits (16,23).”
BackgroundSelf-citationBile acid signaling in the regulation of whole body metabolic and immunological homeostasis
Jia, W., Li, Y., Cheung, K. C. P., & Zheng, X. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2353-0 · Cited by 189
“On the other hand, inhibition of intestinal FXR signaling reduces obesity, insulin resistance and fatty liver disease (Jiang et al., 2015a; Jiang et al., 2015b).”
InfluentialObesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 186
“FXR signaling is activated in distal ileum biopsies from obese humans compared to lean humans, as evidenced by increase in mRNAs encoded by FXR and FXR target genes (Jiang et al, 2015).”
Update on FXR Biology: Promising Therapeutic Target?
Han, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072069 · Cited by 185
“On the other hand, the intestine-selective inhibition of FXR by treatment with glycine-β-muricholic acid, improved HFD-induced and genetic obesity, insulin resistance, and liver steatosis in the mice [121].”
BackgroundRecent advances in understanding bile acid homeostasis
Chiang, J. Y. (2017) · F1000Research · doi:10.12688/f1000research.12449.1 · Cited by 181
The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases
Fogelson, K. A., Dorrestein, P. C., Zarrinpar, A., & Knight, R. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.022 · Cited by 177
“81 Whether these differences are the result of different techniques (eg, mode of administration) or off-target effects is unclear and warrants additional investigation.”
Liu, T.-C., Kern, J. T., Jain, U., Sonnek, N. M., Xiong, S., Simpson, K. F., VanDussen, K. L., Winkler, E. S., Haritunians, T., Malique, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.004 · Cited by 170
Perakakis, N., Stefanakis, K., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154320 · Cited by 162
Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis
Xie, C., Yagai, T., Luo, Y., Liang, X., Chen, T., Wang, Q., Sun, D., Zhao, J., Ramakrishnan, S. K., Sun, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4412 · Cited by 161
Self-citationThe Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism
Yu, Y., Raka, F., & Adeli, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122227 · Cited by 160
“However, another study showed FXR signaling was activated in obese human intestines, and intestine-selective FXR inhibitor improved obesity and metabolic syndrome in HFD-induced obese mice [80].”
BackgroundFXR in liver physiology: Multiple faces to regulate liver metabolism
Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 176
Sun, Y., Zhang, X., Hang, D., Lau, H. C.-H., Du, J., Liu, C., Xie, M., Pan, Y., Wang, L., Liang, C., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.005 · Cited by 179
Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights
Ye, P., Xi, Y., Huang, Z., & Xu, P. (2020) · Cancers · doi:10.3390/cancers12061408 · Cited by 158
“found Glycineβ-muricholic acid (Gly-MCA), an intestine-specific FXR inhibitor, reduced obesity and associated metabolic dysfunction through inhibition of ceramide metabolism [161].”
BackgroundZhang, X., Zhang, Y., Wang, P., Zhang, S., Dong, Y., Zeng, G., Yan, Y., Sun, L., Wu, Q., Liu, H., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.016 · Cited by 162
Self-citationEmerging concepts in intestinal immune control of obesity-related metabolic disease
Khan, S. M., Luck, H., Winer, S., & Winer, D. A. (2021) · Nature Communications · doi:10.1038/s41467-021-22727-7 · Cited by 169
Bile acids and bariatric surgery
Albaugh, V. L., Banan, B., Ajouz, H., Abumrad, N. N., & Flynn, C. R. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.001 · Cited by 148
“…to FXR and leads to increased bile acid synthesis through decreasing intestinal expression of FGF19 (Mueller et al., 2015); selective FXR inhibitors (i.e. glyco-b-tauromuricholic acid) have been effective in reversing obesity and improving associated metabolic parameters (Jiang et al., 2015).”
BackgroundLi, G., Xie, C., Lu, S., Nichols, R. G., Tian, Y., Li, L., Patel, D., Ma, Y., Brocker, C. N., Yan, T., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.007 · Cited by 144
“Although many agents and treatments were reported to induce browning (Bonet et al., 2013; Jiang et al., 2015; Wu et al., 2013), it is unclear how these approaches can translate to clinically relevant therapies for human metabolic disease (Nedergaard and Cannon, 2014).”
Self-citationThe metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Effect of different bile acids on the intestine through enterohepatic circulation based on FXR
Xiang, J., Zhang, Z., Xie, H., Zhang, C., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1949095 · Cited by 149
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139
How bile acids and the microbiota interact to shape host immunity
Lee, M. H., Nuccio, S.-P., Mohanty, I., Hagey, L. R., Dorrestein, P. C., Chu, H., & Raffatellu, M. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01057-x · Cited by 143
“By contrast, the mouse β-muricholic acid derivatives tauro-β-muricholic acid 64 and glyco-β-muricholic acid 69 are FXR antagonists.”
Surface tension and viscosity of protein condensates quantified by micropipette aspiration
Wang, H., Kelley, F. M., Milovanović, D., Schuster, B. S., & Shi, Z. (2021) · Biophysical Reports · doi:10.1016/j.bpr.2021.100011 · Cited by 148
Wu, Q., Sun, L., Hu, X., Wang, X., Xu, F., Chen, B., Liang, X., Xia, J., Wang, P., Aibara, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142865 · Cited by 140
“Notably, inhibition of intestinal FXR signaling protects against highfat diet–induced metabolic diseases, including obesity, insulin resistance, and fatty liver (25, 26, 42).”
BackgroundSelf-citationRodrigues, R. R., Greer, R. L., Dong, X., DSouza, K. N., Gurung, M., Wu, J. Y., Morgun, A., & Shulzhenko, N. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02306 · Cited by 139
“Importance of phenotypes in the network was also determined by degrees of connectedness (degree) and BC. GTTAUC (degree = 14, BC score = 0.65) and liver Fxr (degree = 8, BC score= 0.60) were the highly connected metabolic parameter and gene, respectively, as well as the key nodes in the largest connected component of…”
BackgroundResultInfluentialMan, A. W. C., Zhou, Y., Xia, N., & Li, H. (2020) · Nutrients · doi:10.3390/nu12103054 · Cited by 142
“In addition, recent studies have demonstrated that the activation of intestinal FXR leads to hyperglycemia in obese state, suggesting that inhibition of FXR signaling might be efficient for preventing hyperglycemia [150,151].”
BackgroundJuárez‐Fernández, M., Porras, D., Petrov, P., Román-Sagüillo, S., García‐Mediavilla, M. V., Soluyanova, P., Martínez‐Flórez, S., González‐Gallego, J., Nistal, E., Jover, R., et al. (2021) · Antioxidants · doi:10.3390/antiox10122001 · Cited by 142
“Elevated levels of MCA species lead to a less toxic and hydrophobic BA pool, which has been shown to improve obesity, insulin resistance, and NAFLD [71,72].”
BackgroundProgress and challenges of selective Farnesoid X Receptor modulation
Massafra, V., Pellicciari, R., Gioiello, A., & van Mil, S. W. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.009 · Cited by 140
Contribution of specific ceramides to obesity-associated metabolic diseases
Hammerschmidt, P., & Brüning, J. C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04401-3 · Cited by 142
Ding, Y., Yanagi, K., Cheng, C., Alaniz, R. C., Lee, K., & Jayaraman, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.029 · Cited by 137
Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
Zhang, L., Xie, C., Nichols, R. G., Chan, S. H. J., Jiang, C., Hao, R., Smith, P. B. W., Cai, J., Simons, M., Hatzakis, E., et al. (2016) · mSystems · doi:10.1128/msystems.00070-16 · Cited by 134
Self-citationThe Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 129
Metadata
- Authors
- Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Pennsylvania State University (US)
- Oregon State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-12-15
- Volume
- 6
- Issue
- 1
- Pages
- 10166-10166
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4682112
- OpenAlex
- W2236340720
- Cited by
- 559
- References
- 58
- Citations by year
- 2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Greater South Information System
- Funders
- Pennsylvania Department of Health
- National Natural Science Foundation of China (31401011, 81200626)
- National Institutes of Health
- National Cancer Institute
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
- MeSH terms
- Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.